Nanomedicine News RSS Feed - Nanomedicine

NuVascular Commercializes Nanotechnology-Based Electrospinning Process for Creating Medical Devices

NuVascular Commercializes Nanotechnology-Based Electrospinning Process for Creating Medical Devices

NuVascular Technologies, Inc. is commercializing its patented electrospinning process to create new medical devices that help millions. [More]
French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma

French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma

NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). [More]
Niels Bohr Institute Professor Honored with Prize for 'Research Excellence in Nanotechnology'

Niels Bohr Institute Professor Honored with Prize for 'Research Excellence in Nanotechnology'

Charles Marcus, who is a professor and head of the Center for Quantum Devices at the Niels Bohr Institute at the University of Copenhagen, has been awarded the prize for 'Research Excellence in Nanotechnology' by the nanoscience centre, NBIC at the University of Pennsylvania, USA. It is an international prize and is given in recognition of outstanding research in nanotechnology. [More]
Selecta, JDRF add Sanofi in Partnership to Develop Synthetic Vaccine Particle Immunotherapy for Diabetes

Selecta, JDRF add Sanofi in Partnership to Develop Synthetic Vaccine Particle Immunotherapy for Diabetes

Selecta Biosciences, Inc., and JDRF, announced today that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. [More]
Novavax’s RSV F-Protein Nanoparticle Vaccine Candidate Evokes Polyclonal Antibody Response to Antigenic Site II

Novavax’s RSV F-Protein Nanoparticle Vaccine Candidate Evokes Polyclonal Antibody Response to Antigenic Site II

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that its RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab (Synagis®), resulting in protection from an RSV challenge in an animal model. [More]
Major Advance in Implementation of ETPN Nanomedicine Translation Hub

Major Advance in Implementation of ETPN Nanomedicine Translation Hub

A major step in implementing the ETPN Translation Hub has been reached, with three European projects entering the finalisation stage of their EU Grant Agreements. The project ENATRANS is for networking of SMEs in the nano-biomedical sector and supporting the SMEs with getting their products from the laboratory phase to the clinical applications. [More]
Anticancer Nanomedicines Have an Optimal Particle Size

Anticancer Nanomedicines Have an Optimal Particle Size

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines, in correlation to their biological responses and functions, is crucial for their further development of as cancer-fighters. [More]
Novavax Begins Enrollment in Phase 2 Clinical Trial of RSV F Nanoparticle Vaccine

Novavax Begins Enrollment in Phase 2 Clinical Trial of RSV F Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy elderly subjects. [More]
Enhanced Red-Emission Nanoparticles Combined with Photodynamic Drug Therapy Kills Malignant Cells

Enhanced Red-Emission Nanoparticles Combined with Photodynamic Drug Therapy Kills Malignant Cells

An international group of scientists led by Gang Han, PhD, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors. [More]
Nano-Optics Researchers Develop Light-Based Sensor for Blood Analysis

Nano-Optics Researchers Develop Light-Based Sensor for Blood Analysis

The development is based on optical principles and provides precision and allows saving vital time for the patient. [More]